Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests – Quarterly Update Report

ACB’s German position remains differentiated by local production, direct supply capabilities, and a regulatory infrastructure that becomes more valuable as compliance standards tighten. Germany is ACB’s largest and fastest-growing international market and one of the most stringent globally, with strict GMP standards governing market access. ACB is one of only three active in-country producers holding German production and R&D licenses and has operated in the market since 2018, creating established relationships with wholesalers, distributors, pharmacists, and regulators. The market is primarily structured around flower and oil, with the Leuna expansion now in its final phase and expected to double the facility’s annual flower output as proprietary cultivars are introduced. Combined with Canadian EU-GMP production and Safari’s newly certified capacity, Leuna should improve product availability, shorten supply chains, and support further share gains in a market where high-quality GMP flower remains scarce. Regulatory proposals affecting prescribing and distribution remain monitorable, although ACB’s focus on cultivation and wholesale rather than retail or telehealth limits direct exposure to the downstream channels most likely to be affected.

Poland, Australia, and New Zealand provide additional international growth vectors and reduce reliance on a single European market. ACB retains the number-one share position in Poland, where increased annual import limits and a loyal patient base support further growth despite earlier restrictions on telemedicine prescribing. The company’s experience navigating Poland’s regulatory transition provides a relevant precedent for potential changes in Germany, as more stringent market structures tend to favor scaled operators with established registrations, reliable supply, and pharmaceutical-grade manufacturing. In Australia, ACB is shifting mix toward core and premium offerings as physician and patient demand moves to higher-tier products, while the market’s broad range of permitted formats allows the company to commercialize products beyond flower and oils. New Zealand is also generating encouraging growth as ACB expands its assortment in another tightly regulated medical market. Together, Germany, Poland, Australia, and New Zealand underpin the expectation for international growth to remain the principal offset to Canada during FY27.

The U.K. strategy remains deliberately focused on premium medical supply rather than downstream clinic or pharmacy ownership. While several competitors have vertically integrated into online clinics and pharmacies, ACB continues to prioritize genetics, product development, and GMP manufacturing, where it believes its capabilities and returns are strongest. Regulatory engagement with the MHRA and evolving quality standards should favor suppliers with established pharmaceutical-grade capacity, while the U.K.’s self-pay market places a premium on consistent, high-quality medical products. ACB therefore does not need to replicate competitors’ downstream infrastructure to participate in the market’s growth; instead, its large GMP supply base can support multiple channels while preserving capital and maintaining focus on higher-return cultivation and wholesale economics.

The Canadian medical decline was consistent with the expected reimbursement-rate reset and does not appear to signal deterioration in patient demand or competitive position. Canadian medical revenue declined 25% to C$20.7 million from C$27.7 million as changes to the federal reimbursement program lowered applicable reimbursement rates by approximately 30% effective April 1. The C$7.0 million y/y revenue reduction was therefore closely aligned with the pricing change, while patient eligibility, covered volumes, and authorization mechanics were not identified as material sources of pressure. Canadian medical represented 31% of consolidated revenue versus 37% a year earlier, and the shift was the principal factor behind lower adjusted gross profit and EBITDA. While the reimbursement change creates a meaningful near-term earnings reset because cultivation and fulfillment costs do not decline proportionately with realized pricing, the first-quarter result supports the view that the issue is principally economic rather than demand-driven.

Canadian medical retains an underlying share-growth opportunity despite the reimbursement reset, with ACB’s veteran-service expertise potentially portable across markets. Veteran medical-cannabis penetration has increased from approximately 4% to 8% over the past four years, while new patients continue entering the system across age groups, genders, and medical indications. Although management did not provide a natural penetration ceiling, it continues to see scope for ACB to gain share through its service model, product availability, and direct patient relationships. The operating insight also extends beyond Canada, as veteran communities in the U.S., Australia, and New Zealand exhibit similar interest in medical cannabis and maintain close cross-border connections. This creates a potentially scalable patient-acquisition and retention capability that could support international growth without requiring ACB to alter its cultivation- and medical-product-led strategy.

The U.S. remains a longer-duration strategic and partnership opportunity rather than a near-term earnings driver. ACB identified three potential avenues from federal rescheduling: expanded research collaboration, partnerships leveraging its GMP and medical-grade manufacturing standards, and longer-term import-export opportunities between the U.S. and the international medical markets it already serves. While U.S. operators could eventually become competitors in international markets, ACB believes its decade-plus experience in EU-GMP manufacturing, integrated cultivation model, and established presence in regulated markets such as Germany provide meaningful advantages and could also position it as a partner to operators lacking comparable international regulatory and supply-chain capabilities. However, no specific partnership, investment, or revenue timeline was provided, leaving the opportunity as longer-term optionality pending regulatory clarity.

The consumer cannabis wind-down continued to improve business quality, although clearance activity pressured the remaining segment’s margin. Consumer cannabis revenue declined 74% to C$2.1 million from C$7.9 million as ACB exits lower-margin Canadian recreational channels and reallocates resources to medical cannabis. Consumer adjusted gross margin declined to 20% from 33%, largely because products were sold at reduced prices to minimize inventory impairment during the wind-down. Consumer cannabis now represents only 3% of consolidated revenue compared with 11% a year ago, limiting its future impact on reported results and positioning ACB for a cleaner medical-only earnings base. Wholesale bulk cannabis revenue was C$1.5 million versus C$1.4 million y/y, leaving the company’s revenue mix overwhelmingly concentrated in medical channels with greater regulatory barriers, better visibility, and structurally higher margins.

Capital allocation remains focused on international capacity and selective M&A, although recent equity issuance increases the importance of per-share returns. ACB issued 1.58 million shares through its ATM program at an average gross price of C$4.29, raising C$6.7 million net, while 2.42 million shares were issued as consideration for Safari. As a result, shares outstanding increased 7% during the quarter to 63.31 million from 58.95 million. The issuance provides additional flexibility for acquisitions and internal investment, but future capital deployment should be assessed against revenue, EBITDA, and free-cash-flow accretion given ACB’s substantial liquidity and debt-free balance sheet.

Management reaffirmed FY27 guidance, with international growth and manufacturing efficiencies expected to partially offset the Canadian pricing reset. FY27 remains a transition year as the VAC reimbursement change pressures revenue and adjusted EBITDA, although ACB expects to gain share in Canadian medical while continued growth in Germany, Poland, Australia, and New Zealand supports sequential improvement. Germany remains the largest and most visible growth driver, supported by strong patient demand and limited availability of high-quality EU-GMP flower. On the cost side, ACB continues to target efficiencies through proprietary genetics and facility optimization, with certain cultivars capable of improving yields by up to 40% while also enhancing quality, potency, and terpene profiles. The 58% adjusted gross margin in 1Q reached the high end of the annual target range, and ACB reiterated that 2Q revenue and adjusted EBITDA should be substantially higher than in 1Q.